Lupus drug in breast milk: new study aims to answer safety questions
NCT ID NCT06594068
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This study is tracking 16 mothers with lupus who are already taking the drug anifrolumab and breastfeeding. Researchers will measure how much of the drug passes into breast milk and into the mother's and baby's blood. The goal is to better understand the safety of using anifrolumab while nursing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGLas Vegas, Nevada, 89113, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anifrolumab
What this could lead to
If successful, this study could provide crucial safety data to help mothers with lupus make informed decisions about breastfeeding while on anifrolumab.
What could go wrong
This is a very small observational study (16 participants) that only measures drug levels, not health outcomes. It cannot prove the drug is safe for infants.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.